Survival times of EM AML patients according to ELN2017 groups | HCT | no HCT | Hazard ratio | Cox regression p-value |
---|---|---|---|---|
ELN2017 favorable | n = 20 | n = 61 |  |  |
 Event-free survival | 13.5 [4.8-n.r.] | 12.6 [7.8–27.5] | 0.86 [0.45–1.65] | 0.659 |
 Relapse-free survival | 29.0 [7.5-n.r.] | 43.6 [12.6-n.r.] | 1.35 [0.66–2.78] | 0.410 |
 Overall survival | 54.0 [11.0-n.r.] | 27.2 [13.6-n.r.] | 0.81 [0.41–1.59] | 0.537 |
ELN2017 intermediate | n = 22 | n = 55 |  |  |
 Event-free survival | 9.1 [3.7–44.1] | 3.6 [1.8–7.5] | 0.55 [0.32–0.98] | 0.043 |
 Relapse-free survival | 10.8 [4.6-n.r.] | 8.4 [2.1–14.4] | 0.69 [0.35–1.35] | 0.277 |
 Overall survival | 44.1 [9.1-n.r.] | 7.5 [3.6–13.1] | 0.40 [0.21–0.77] | 0.006 |
ELN2017 adverse | n = 23 | n = 33 |  |  |
 Event-free survival | 7.4 [1.1–13.6] | 1.2 [0.3–3.0] | 0.48 [0.27–0.85] | 0.013 |
 Relapse-free survival | 11.6 [4.2–44.0] | 6.0 [2.3–9.8] | 0.51 [0.24–1.08] | 0.077 |
 Overall survival | 21.0 [13.6–48.4] | 7.1 [3.1–9.2] | 0.31 [0.17–0.58] |  < 0.001 |